Several PET/CT facilities in Sydney and Perth attest to the efficiency, high yield and ease of use of kit technology in providing 68Ga-PSMA-11 for routine clinical prostate cancer imaging [57]. This evidence concerns the gene FOLH1 and prostate carcinoma.